![Christine, 2008 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (12)
Similar to C6 HIV 201 Armas
Similar to C6 HIV 201 Armas (20)
More from DSHS
More from DSHS (13)
Recently uploaded
Recently uploaded (20)
C6 HIV 201 Armas
- 1. HIV 201 Laura N Armas-Kolostroubis MD Clinical Director Texas/Oklahoma AIDS Education and Training Center
- 5. Christine, 2008 HBV HBsAg HBsAb HBc Ab HBeAg HBeAb IgG IgM Incubating + - - - +/- - Acute Infection + - +/- + + - Chronic Carrier + - + - - + Chronic Infection + - + - + - Resolved Infection - + + - - + Immune - + - - - -
- 6. Christine, 2008 HBV HBsAg HBsAb HBc Ab HBeAg HBeAb IgG IgM Incubating + - - - +/- - Acute Infection + - +/- + + - Chronic Carrier + - + - - + Chronic Infection + - + - + - Resolved Infection - + + - - + Immune - + - - - -
- 19. A few months ago noticed the following lesion, but did not seek medical attention
- 32. Risk factors of MI in HIV infected patients Costagliola, IAS 2009 Controls N=1151 Cases N=278 OR [95% CI ] CV risk factors 0 173 5 1 1 or 2 710 166 16.8 (5.9 – 48.4) 3 or more 268 107 49.4 (16.4 – 149,0) Plasma HIV-1 RNA <= 50 copies/ml 573 121 1 > 50 copies/ml 578 157 1.6 (1,1 – 2,1) CD4 / CD8 ratio >= 1 135 19 1 < 1 1016 259 1.8 (1,0 – 3,0)
- 48. HIV REVERSE TRANSCRIPTASE CANNOT PROOF READ C HIV RNA T U T T A G A A G G A G C C T C HIV DNA
- 50. RELATIONSHIP BETWEEN ADHERENCE AND VIRAL LOAD P <0.01 % of PI Doses Taken
- 51. EFFECTS OF SPONTANEOUS MUTATIONS ON VIRAL SWARMS Wild Type HIV Dead End HIV Resistant HIV
- 52. EFFECT OF SELECTIVE PRESSURE OF INSUFFICIENT ART Wild Type HIV Resistant HIV Dead End HIV
- 57. Adherence Access to care Access to medication Life situation Disease stage Challenges to Successful ART: Considerations When Initiating Therapy Replication rate (Viral load) Mutation rate (Resistance) Latent HIV reservoirs Potency Pharmacokinetics (dosage schedule) Tolerability Toxicity Convenience Resistance Clinician experience Communication skills Virus Drug Clinician Patient
- 63. Etravirine Score Response Rate 0-2 74% 2.5-3.5 52% 4 or greater 38%
Editor's Notes
- Answer is b, a elite controller
- Second study provides additional information on possible utility of using double dose HBV vaccination in non-responders (also recommended by hepatologist speaker at RWCA clinical update conference 2009) First study – accelerated vaccine schedule proposed as option for thiose who are less likely to finish traditional dosing schedule
- Answer is a
- Answer is e
- Correct answer is c
- Since the introduction of HAART, an increase in STIs has been observed in MSMs who are aware of their HIV + status. Many of these STI may be asymptomatic. The question is whether regular STI screening should be considered for all HIV-infected MSM.
- Correct answer is b
- Correct answer is e
- Correct answer is b
- Correct answer is c
- Correct answer is c
- Answer is e (all of the above)
- Answer is e (all of the above)
- Slide #5: Challenges to Successful ART: Considerations When Initiating Therapy This Venn diagram illustrates the four interrelated components that play a role in determining successful outcomes with antiretroviral therapy and therefore should be addressed when initiating treatment. Designing a general strategy for interventions specific to each of these components right from the beginning of treatment is a key factor in the overall success of anti-HIV therapy.
- Correct answer is e
- Collect the answers but no correct answer
- A cumulative score of 0 to 2 is associated with a 74% response rate, whereas cumulative scores of 2.5 to 3.5 and 4.0 or greater are associated with response rates of 52% and 38%, respectively. 38 Presence of the K103N mutation at baseline is not associated with a reduced virological response. 39